CDTX vs MGNX vs IMVT vs CRL vs IQV

For growth investors, IQVIA Holdings Inc.

(IQV) is the stronger pick with 5. 9% revenue growth year-over-year, versus -94. 5% for Cidara Therapeutics, Inc. (CDTX). IQVIA Holdings Inc. (IQV) offers the better valuation at 22. 8x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Cidara Therapeutics, Inc. (CDTX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, IQVIA Holdings Inc.

is actually cheaper at 14. 1x.

Over the past 5 years, Cidara Therapeutics, Inc.

(CDTX) delivered a total return of +450. 7%, compared to -90. 8% for MacroGenics, Inc. (MGNX). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus MGNX's -84. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Cidara Therapeutics, Inc.

(CDTX) is the lower-risk stock at 0. 87β versus MacroGenics, Inc. 's 1. 93β — meaning MGNX is approximately 123% more volatile than CDTX relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), IQVIA Holdings Inc.

(IQV) is pulling ahead at 5. 9% versus -94. 5% for Cidara Therapeutics, Inc. (CDTX). On earnings-per-share growth, the picture is similar: IQVIA Holdings Inc. grew EPS 4. 7% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, IQV leads at 4. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

IQVIA Holdings Inc.

(IQV) is the more profitable company, earning 8. 3% net margin versus -133. 2% for Cidara Therapeutics, Inc. — meaning it keeps 8. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IQV leads at 14. 0% versus -138. 1% for CDTX. At the gross margin level — before operating expenses — CDTX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, IQVIA Holdings Inc.

(IQV) trades at 14. 1x forward P/E versus 16. 4x for Charles River Laboratories International, Inc. — 2. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MGNX: 104. 1% to $6. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Cidara Therapeutics, Inc.

(CDTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 87)). MacroGenics, Inc. (MGNX) carries a higher beta of 1. 93 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CDTX: -16. 0%, MGNX: -84. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.